Follow
Marcelo Eduardo Bigal
Marcelo Eduardo Bigal
Head of the Merck Investigator Sudies Program, Scientific Engagements and Education
Verified email at merck.com
Title
Cited by
Cited by
Year
Heart disease and stroke statistics—2013 update: a report from the American Heart Association
AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, WB Borden, ...
circulation 127 (1), e6-e245, 2013
59543*2013
The international classification of headache disorders, (beta version)
Headache Classification Committee of the International Headache Society (IHS)
Cephalalgia 33 (9), 629-808, 2013
125582013
Migraine prevalence, disease burden, and the need for preventive therapy
RB Lipton, ME Bigal, M Diamond, F Freitag, ML Reed, WF Stewart
Neurology 68 (5), 343-349, 2007
29182007
Migraine and cardiovascular disease: systematic review and meta-analysis
M Schürks, PM Rist, ME Bigal, JE Buring, RB Lipton, T Kurth
Bmj 339, 2009
10692009
Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population‐based study
ME Bigal, D Serrano, D Buse, A Scher, WF Stewart, RB Lipton
Headache: The Journal of Head and Face Pain 48 (8), 1157-1168, 2008
10412008
Fremanezumab for the preventive treatment of chronic migraine
SD Silberstein, DW Dodick, ME Bigal, PP Yeung, PJ Goadsby, ...
New England Journal of Medicine 377 (22), 2113-2122, 2017
8502017
Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment
ME Bigal, D Serrano, M Reed, RB Lipton
Neurology 71 (8), 559-566, 2008
839*2008
Cutaneous allodynia in the migraine population
RB Lipton, ME Bigal, S Ashina, R Burstein, S Silberstein, ML Reed, ...
Annals of neurology 63 (2), 148-158, 2008
6592008
The international classification of headache disorders, (beta version)
DA Ettlin
Cephalalgia 33 (9), 629-808, 2013
6572013
Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial
DW Dodick, SD Silberstein, ME Bigal, PP Yeung, PJ Goadsby, ...
Jama 319 (19), 1999-2008, 2018
6092018
Migraine: epidemiology, impact, and risk factors for progression
RB Lipton, ME Bigal
Headache: The Journal of Head and Face Pain 45, S3-S13, 2005
5932005
Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double‐blind, placebo‐controlled trial
SD Silberstein, RB Lipton, DW Dodick, FG Freitag, N Ramadan, ...
Headache: The Journal of Head and Face Pain 47 (2), 170-180, 2007
5882007
Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study: CME
S Diamond, ME Bigal, S Silberstein, E Loder, M Reed, RB Lipton
Headache: The Journal of Head and Face Pain 47 (3), 355-363, 2007
5722007
Obesity and migraine: a population study
ME Bigal, JN Liberman, RB Lipton
Neurology 66 (4), 545-550, 2006
5252006
Modifiable risk factors for migraine progression
ME Bigal, RB Lipton
Headache: The Journal of Head and Face Pain 46 (9), 1334-1343, 2006
4792006
Migraine and cardiovascular disease: a population-based study
ME Bigal, T Kurth, N Santanello, D Buse, W Golden, M Robbins, ...
Neurology 74 (8), 628-635, 2010
4742010
Symptoms of temporomandibular disorders in the population: an epidemiological study.
DA de Godoi Gonçalves, AL Dal Fabbro, JADB Campos, ME Bigal, ...
Journal of orofacial pain 24 (3), 2010
4642010
Prevalence and characteristics of allodynia in headache sufferers: a population study
ME Bigal, S Ashina, R Burstein, ML Reed, D Buse, D Serrano, RB Lipton
Neurology 70 (17), 1525-1533, 2008
4522008
Obesity is a risk factor for transformed migraine but not chronic tension-type headache
ME Bigal, RB Lipton
Neurology 67 (2), 252-257, 2006
4242006
Chronic disorders with episodic manifestations: focus on epilepsy and migraine
SR Haut, ME Bigal, RB Lipton
The Lancet Neurology 5 (2), 148-157, 2006
4132006
The system can't perform the operation now. Try again later.
Articles 1–20